Search results for "Ingenol Mebutate Gel"

showing 3 items of 3 documents

Successful treatment of condylomata acuminata at the urethral meatus with high-dose ingenol mebutate gel: Report of two cases

2019

Condylomata acuminata (CA), or anogenital warts, is the most common sexually transmitted infection. Treatments for CA generally have suboptimal recurrence rates, which results in a need for repeated treatments and adds to the already negative impact on the patients’ quality of life. CA can present at the urethral meatus, which is a particularly challenging anatomic location from a therapeutic perspective. We report two cases of CA at the urethral meatus successfully treated with topical application of high-dose ingenol mebutate gel.

AdultMalemedicine.medical_specialtyIngenol Mebutate GelPenile DiseasesAdolescentTreatment outcomeIngenol mebutateDermatologyGenital warts03 medical and health scienceschemistry.chemical_compound0302 clinical medicinemedicineHumansPharmacology (medical)030212 general & internal medicineHuman papillomavirusAnatomic LocationPapillomaviridaeUrethral meatus030505 public healthbusiness.industryPublic Health Environmental and Occupational Healthvirus diseasesmedicine.diseaseDermatologyTreatment OutcomeInfectious DiseaseschemistryCondylomata AcuminataDiterpenes0305 other medical sciencebusinessGelsInternational Journal of STD & AIDS
researchProduct

An exploratory, prospective, open-label trial of ingenol mebutate gel 0.05% for the treatment of external anogenital warts

2017

BACKGROUND Anogenital warts (AGW) can cause physical discomfort and decreased quality of life. Recent case reports suggest that ingenol mebutate gel might be an effective treatment of AGW. OBJECTIVE To explore primarily the safety, and secondarily the efficacy of ingenol mebutate gel 0.05% in patients with AGW. METHODS This was an exploratory, open-label, 1-arm trial of ingenol mebutate gel 0.05% administered up to three times to patients with AGW. Safety was assessed by occurrence and severity of local skin reactions (LSRs) and treatment-related adverse events (AEs). Efficacy was assessed by complete clearance and reduction in AGW count 14 days after last treatment, and recurrence 12 weeks…

AdultMaleIngenol Mebutate Gelmedicine.medical_specialtyPopulationPainAntineoplastic AgentsDermatologyYoung Adult030207 dermatology & venereal diseases03 medical and health sciencesBlister0302 clinical medicineQuality of lifeRecurrenceInternal medicineSkin UlcermedicineEdemaHumansEffective treatmentIn patientProspective Studies030212 general & internal medicineAdverse effecteducationAgedAnus Diseaseseducation.field_of_studybusiness.industryMiddle AgedSafety profileTreatment OutcomeInfectious DiseasesCondylomata AcuminataErythemaFemaleDiterpenesGenital Diseases MaleOpen labelbusinessGelsGenital Diseases FemaleJournal of the European Academy of Dermatology and Venereology
researchProduct

Ingenol mebutate gel is effective against anogenital warts - a case series in 17 patients.

2015

AdultMaleIngenol Mebutate Gelmedicine.medical_specialtyAnus Diseasesbusiness.industryDermatologyMiddle AgedDermatology030207 dermatology & venereal diseases03 medical and health sciencesYoung Adult0302 clinical medicineInfectious DiseasesCondylomata AcuminatamedicineHumansFemale030212 general & internal medicineDiterpenesGenital Diseases MalebusinessGenital Diseases FemaleAgedJournal of the European Academy of Dermatology and Venereology : JEADV
researchProduct